NAD+ injections, IV drips and oral precursors: what actually differs

What NAD+ is, in one paragraph that is not hype

Nicotinamide adenine dinucleotide is a coenzyme present in every cell you have. Its main job is to carry electrons in the reactions that turn food into usable energy. It is also consumed as a raw material by several families of enzymes, ones involved in DNA repair and in regulating how genes are switched on and off. Cells make it continuously from precursors, and several of those enzymes destroy it as they work, so the pool is constantly turning over.

That much is settled biochemistry and nobody argues about it. The commercial claim built on top of it has three parts. The first is that cellular NAD+ declines with age and with metabolic stress. The second is that this decline contributes to how aging feels. The third is that topping the pool back up reverses some of it. The first part has meaningful support. The last part is where the market gets ahead of the evidence, and the delivery route you are being sold determines how far ahead.

The routes are chemically different problems, not price tiers

Clinics tend to present oral capsules, subcutaneous or intramuscular injection, and an intravenous drip as a ladder — cheapest to most effective. That framing does not survive contact with the pharmacology, because the three routes are not delivering the same molecule to the same place.

NAD+ is a large, charged molecule and cells do not simply absorb it whole. Outside the cell it is broken down by surface enzymes into smaller pieces, and those pieces are taken up and used to rebuild NAD+ inside the cell. This matters enormously for reading any of these products. Putting NAD+ into a vein does not put NAD+ into a cell. It raises the concentration of NAD+ and its breakdown products in the blood, and the cell then does what it was always going to do with the fragments.

Once you understand that, the supposed ladder collapses. An intravenous drip is not a stronger version of a capsule. It is an expensive way of presenting the body with material it is going to dismantle anyway. The argument that it works better has to rest on evidence, not on the intuition that injecting something must beat swallowing it.

Oral precursors: the part of this category with real human data

The oral products are usually not NAD+ itself. They are precursors — most commonly nicotinamide riboside or nicotinamide mononucleotide, sometimes plain nicotinamide or niacin, which are the oldest and cheapest members of the family.

Nicotinamide riboside in particular has been through repeated human trials. Those trials consistently show what they were designed to show: taking it raises measurable NAD+ levels in blood, in a dose-related way. This is the strongest replicated human finding anywhere in the NAD+ category, and it is the main reason the evidence grade here is limited rather than absent.

What those trials have generally not shown is the second step. Raising the marker has not reliably translated into the clinical outcomes the category is sold on — more energy, better cognition, improved physical function, slower aging. Trials have tended to be small, short, and focused on biomarkers and safety rather than on outcomes a person would notice. Where functional outcomes have been measured, the results have been inconsistent rather than convincing. The honest position is that the pharmacology is established and the benefit is not.

Intravenous NAD+: the most expensive route with the least behind it

Intravenous NAD+ is marketed for fatigue, brain fog, cognitive performance, athletic recovery, and — most aggressively — as a support for withdrawal and addiction recovery. Those are serious claims, and they carry the widest gap between what is advertised and what has been published.

The human work on intravenous NAD+ has been small. It has mostly examined what happens to the molecule after it goes in: how blood levels move, how quickly it is broken down, where the fragments appear. That is pharmacokinetics. It is a legitimate first step, but it is not evidence of clinical benefit. No body of adequately controlled outcome trials has been published for the uses these drips are sold for, and the small studies that do exist are not that body of work.

There is also a practical detail the clinics themselves acknowledge, and it tells you something about the pharmacology. Infusing NAD+ quickly commonly produces chest tightness, flushing, nausea and abdominal cramping, which is why these drips are run slowly over a long session. That is not a safety verdict. It is a well-known characteristic of the route, and a reminder that the body reacts to this material rather than quietly absorbing it.

Subcutaneous and intramuscular injection: the least studied of the three

Injectable NAD+ sold for use outside a clinic sits between the other two routes commercially and below both of them evidentially. It avoids the multi-hour infusion session, which is its entire practical selling point.

The published human literature specific to this route is thin. What is known about it is largely inferred from the intravenous work plus the general pharmacology of the molecule, which is a chain of reasoning rather than a finding. When a product's case rests on an inference from another route, that is worth saying plainly. Otherwise the evidence behind the oral precursors gets quietly borrowed by everything else in the category.

The regulatory picture, which is genuinely unresolved

The standing of some oral NAD+ precursors as dietary supplement ingredients has been disputed with the FDA and is not settled. Injectable and intravenous NAD+ preparations are compounded products rather than FDA-approved drugs. Neither question is predicted here, and no outcome, date or likelihood is asserted for either one.

The practically useful part is what compounded means: the preparation has not been reviewed by the FDA for safety, effectiveness or manufacturing quality. That describes the review pathway. It is not an allegation about any specific pharmacy or clinic.

This page describes what is known about the compound and the routes. It carries no dosing or infusion information and is not usage guidance.

How we graded this

NAD+ is graded limited evidence. The biochemistry is real and uncontested. The decline in NAD+ availability with age has meaningful support. Oral precursors have been shown repeatedly in humans to do the pharmacological thing they claim to do. That is more than a mechanism on a slide.

But the grade is carried almost entirely by the oral precursor literature, and it does not transfer evenly across the category. A reader buying an intravenous drip is buying the most expensive route with the least published support for the outcomes it is sold on. The grade on the page is being earned by capsules. That asymmetry is the single most useful thing to take away.

What would raise the grade is not more biomarker work. It is trials that measure whether people function better, in the population being sold the product, against a placebo, over a period long enough to matter. When that exists, the grade gets re-read and reset.